Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
14 September 2022 - 06:31AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2022
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T
Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): ¨
EXPLANATORY NOTE
AnPac Bio-Medical Science Co., Ltd. (the “Company”) has
received a Staff determination letter (the “Letter”) from the
Listing Qualifications Department of The Nasdaq Stock Market LLC
(“Nasdaq”) dated September 9, 2022, notifying the Company of
the Staff’s determination to delist the Company’s securities from
The Nasdaq Capital Market because of the Company’s failure to
regain compliance with the $1 per share bid price requirement of
Listed Securities required for continued listing as set forth in
Listing Rule 5450(a)(1) (the “$1 Bid Rule”).
Pursuant to the Letter, unless the Company requests an appeal of
the Letter, trading of the Company’s American Depositary Shares
will be suspended at the opening of business on September 20,
2022, and a Form 25-NSE will be filed with the Securities and
Exchange Commission (the “SEC”) to remove the Company’s securities
from listing and registration on the Nasdaq Stock Market. The
Company has the option to appeal the delisting determination and
intends to do so.
The Company intends to appeal the Staff’s determination to a
Hearings Panel (the “Panel”). Such a request will allow the
Company’s American Depositary Shares to continue to be traded
(listed) pending the Panel’s decision.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
|
AnPac
Bio-Medical Science Co., Ltd. |
|
|
|
By: |
/s/
Dr. Chris Chang Yu |
|
|
Name: |
Dr. Chris
Chang Yu |
|
|
Title: |
Co-Chairman
of the Board of Directors and Co-Chief Executive
Officer |
Dated: September 13, 2022
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to May 2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From May 2022 to May 2023